PGLA PEG Copolymer-Based Paclitaxel
Cancer Terms ->
Drugs and Chemicals ->
Pharmacologic Substance ->
Antineoplastic Agent ->
Antimitotic Agent ->
Tubulin Binding Agent ->
Taxane-Site Binding Agent ->
Paclitaxel Preparation -> PGLA PEG Copolymer-Based Paclitaxel
PGLA PEG Copolymer-Based Paclitaxel Definition
A controlled-release, intratumoral paclitaxel formulation in which paclitaxel is incorporated into a thermosensitive, biodegradable triblock copolymer consisting of poly(lactide-co-glycolide) (PLGA) and polyethylene glycol (PEG). Upon intratumoral injection, paclitaxel is released slowly and continuously into tumor tissues from the gelled thermosensitive triblock copolymer over a period of 4 to 6 weeks; in tumor cells, paclitaxel binds to tubulin and inhibits the disassembly-assembly dynamics of microtubules, resulting in cell cycle arrest and cell death. The thermosensitive triblock copolymer component of this formulation transforms from a water-soluble polymer at room temperature to a water-insoluble, biodegradable gel depot at body temperature; intratumoral controlled-release of paclitaxel from the gel minimizes systemic exposure to paclitaxel and the paclitaxel toxicity profile.
PGLA PEG Copolymer-Based Paclitaxel Synonyms
PGLA/PEG Copolymer-Based Paclitaxel, OncoGel
Terms in PGLA PEG Copolymer-Based Paclitaxel category
Copyright © Cancer Terms 2014 All rights reserved. | Terms of Use | Low Carb Foods
No reproduction or republication permitted.